Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 16/20 | 0.50 |
| ▸ | PLK1 | P53350 | 2/20 | 0.50 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8513926 | 0.98 | WEE1 (0.48) | WEE1PLK1BTKTNK2AXL | |
| SCHEMBL217692 | 0.90 | WEE1 (0.51) | WEE1PLK1BTKTNK2AXL | |
| SCHEMBL8513410 | 0.89 | WEE1 (0.47) | WEE1PLK1BTKTNK2 | |
| SCHEMBL189352 | 0.86 | WEE1 (0.52) | WEE1PLK1BTKTNK2AXL | |
| SCHEMBL218477 | 0.85 | WEE1 (0.46) | WEE1PLK1BTKTNK2AXL | |
| SCHEMBL214278 | 0.85 | WEE1 (0.51) | WEE1PLK1BTKTNK2AXL | |
| SCHEMBL214363 | 0.84 | WEE1 (0.50) | WEE1PLK1BTKTNK2AXL | |
| SCHEMBL8510826 | 0.84 | TNK2 (0.49) | WEE1TNK2 | |
| SCHEMBL213487 | 0.84 | WEE1 (0.43) | WEE1PLK1BTKTNK2AXL | |
| SCHEMBL213397 | 0.83 | WEE1 (0.49) | WEE1PLK1BTKTNK2AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | WEE1, WEE2, DCK | WEE1 1/4885PLK1 636/4885BTK 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.